Pills on a US dollar bill

药物研发巨型基金

西雅图—某些公司哄抬价格的行为引起了关注,但有一个令人担忧的情况还没有水落石出。现有药物(包括非专利药)价格增幅过快背后的动机并不仅仅是唯利是图,而是对研发新药可行性的深切怀疑。这一怀疑不无道理。

传统药物研发融资模式岌岌可危。在美国和其他许多发达国家,虽然一些利润最大的药物专利已经过期,但向市场推出新药的平均成本仍然水涨船高。风险资本纷纷从初创生命科学公司退出,大型制药公司每一美元研发支出所对应的上市新药数量也在下降

事实上,平均而言,在早期研究阶段被认为具有潜在用途的化合物中,只有万分之一能够最终获得监管者的批准。批准过程可能长达15年,过于谨小慎微。即使进入了人类临床试验阶段,也只有五分之一能够跨越这一最后一关。

To continue reading, please log in or enter your email address.

To read this article from our archive, please log in or register now. After entering your email, you'll have access to two free articles from our archive every month. For unlimited access to Project Syndicate, subscribe now.

required

By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in

http://prosyn.org/JUTV95i/zh;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.